Biomarkers for determining the prognosis in chronic myelogenous leukemia - Wikidata - wikimedia - TriplyDB

Biomarkers for determining the prognosis in chronic myelogenous leukemia

Biomarkers for determining the prognosis in chronic myelogenous leukemia

http://www.wikidata.org/entity/Q26824660

about

Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia.Personalized medicine in hematology - A landmark from bench to bed An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article.Cytogenetic and Molecular Analyses of Philadelphia Chromosome Variants in CML (chronic myeloid leukemia) Patients from Sindh using Karyotyping and RT-PCR.Intelligent Techniques Using Molecular Data Analysis in Leukaemia: An Opportunity for Personalized Medicine Support System.Diversity of breakpoints of variant Philadelphia chromosomes in chronic myeloid leukemia in Brazilian patients.Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation Alteration of gene expression profile following PPP2R5C knockdown may be associated with proliferation suppression and increased apoptosis of K562 cells.Establishment and genetic characterization of a novel mixed-phenotype acute leukemia cell line with EP300-ZNF384 fusion.

P2860

Q26738514-A77876ED-B6AD-4032-9BF0-347D91852D20 Q36237990-B393452F-A868-4E23-942D-574F6D6C4449 Q38263199-47D35409-E315-4BB8-B83E-F16A193FFC06 Q38672008-5500D3DC-EAF4-4359-9D95-972737236544 Q40474177-1D325AF1-AC70-48A1-8A6C-AC3EFEFDEA67 Q41294047-E33168EB-4853-44F4-B213-61435DC130AD Q41358956-FB31B075-A9EA-4040-852F-1FA55D9BD8E4 Q41463339-42863C08-5C82-4FAA-B762-049936FCE8BB Q42413767-D4643E03-BE18-4359-BAB7-FAD8F83509B2 Q42581908-7AADAB3F-9C25-4716-86FD-9C9B525D0D13 Q42741851-A2C375E5-C532-4B19-8A1E-690880D3F7D5

P2860

Biomarkers for determining the prognosis in chronic myelogenous leukemia

http://www.wikidata.org/entity/Q26824660

description

2013 nî lūn-bûn

@nan

2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@ast

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@en

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@nl

type

label

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@ast

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@en

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@nl

prefLabel

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@ast

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@en

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@nl

P1433

Q26824660-084275EA-56EA-471D-B911-8E98ABE48ABC

P1476

Q26824660-D899D2E8-E014-4AC4-BDF5-B01B19FCC0B4

P2093

Q26824660-9575E080-3C71-4FB5-8A5B-EC7CAF552AA8

Q26824660-B2B4E169-CBB0-4F1E-9ABD-C3BCAD880B26

Q26824660-D4FEA5B2-58B6-477B-B919-996C8DD323E6

P275

Q26824660-8E9D3489-FE1C-4F4A-A1A1-B58EBFF77B1B

P2860

Q26824660-07B8DE4E-6434-4934-9633-E9348A41FE04

Q26824660-1021004C-35EF-4914-AAFF-63152950768A

Q26824660-14E7ACD3-E111-4026-9183-735196579009

Q26824660-1DA9CB20-08BC-41A6-97BB-008475F08AF6

Q26824660-1EF93C31-8141-4155-BD43-A4E6B50D6DC6

Q26824660-2798859D-5A23-4171-822C-66A3DEC382EB

Q26824660-27A6E2D6-4CD0-4CCE-AD3A-FE197FEE885C

Q26824660-2887407A-ED8C-4CDA-839B-5B5BB24F36B6

Q26824660-3B31E8C6-5BD9-4A1D-BA4B-DBF8B768EF7F

Q26824660-4A84FF35-05C5-4899-838B-F86265313855

P2888

Q26824660-9AA94B7D-19B6-49B7-B883-1292DFCAB1CD

P304

Q26824660-E2A03BD4-9B57-4401-8FAF-0778D893D621

P31

Q26824660-05454396-1856-450F-9593-05AE81B9C74E

Q26824660-0D524C00-6453-4383-B75E-A2613D01C088

P3181

Q26824660-F81323E1-8F72-4AC4-B06C-F66717618661

P356

Q26824660-A74AAC36-1BCA-4876-BF4B-B5F44D23D2ED

P407

Q26824660-612CFB13-58E3-4C0A-B2B2-2DDFDDE3D380

P478

Q26824660-84A249ED-8435-4A80-B2EF-0DC4B282B2F6

P5008

Q26824660-47B1EE86-084F-440E-8F87-FD7C156DE13C

P577

Q26824660-4531AD4F-3114-4A45-AA34-BED5EBFEA837

P5875

Q26824660-91C29AAE-1B53-469D-93D5-32976D0B52E8

P6179

Q26824660-31805B2E-6212-4770-A12F-DA5BA00C5F8F

P698

Q26824660-69B7FD31-007B-474A-9D38-6343E706B7B8

P921

Q26824660-72AE135E-7B9C-4D50-98E9-C3DAC2CF2206

Q26824660-844C870A-2A11-45D2-B596-5DD0B4DB71A0

Q26824660-9AC26D12-7DD5-4ABF-9332-E48794D74140

Q26824660-A7529CB7-6E97-4D50-9601-B0E43A53DB49

P932

Q26824660-F5449412-21EF-40EF-B316-E30D6C657221

P3181

P356

P1433

Journal of Hematology & Oncology

P1476

Biomarkers for determining the prognosis in chronic myelogenous leukemia

@en

P2093

Javier Pinilla-Ibarz

http://www.w3.org/2001/XMLSchema#string

Kendra Sweet

http://www.w3.org/2001/XMLSchema#string

Ling Zhang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.0 Generic

P2860

Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

The molecular biology of chronic myeloid leukemia.

Predicting relapse prior to transplantation in chronic myeloid leukemia by integrating expert knowledge and expression data

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Gene expression changes associated with progression and response in chronic myeloid leukemia.

P2888

P304

54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4158367

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/1756-8722-6-54

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P5008

P577

2013-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

250921918

http://www.w3.org/2001/XMLSchema#string

P6179

1029143566

http://www.w3.org/2001/XMLSchema#string

P698

23870290

http://www.w3.org/2001/XMLSchema#string

P921

tumor biomarkers

chronic myeloid leukemia

P932

3737033

http://www.w3.org/2001/XMLSchema#string